Demographic and mean baseline data for all subjects and subjects completing the study
| Variable | All subjects | Completed subjects | |||
|---|---|---|---|---|---|
| BUD | BDP | Reference | |||
| No (% female) | 374 (55) | 87 (56) | 74 (56) | 78 (49) | |
| Mean (SD) age (years) | 35 (11) | 37 (11) | 36 (12) | 36 (10) | |
| Weight (kg) | 70 | 70 | 73 | 71 | |
| Duration of asthma (years) | 13 | 13 | 13 | 13 | |
| Smoking (% current) | 20 | 19 | 17 | 22 | |
| Morning PEF (l/min) | 407 | 403 | 411 | 411 | |
| FEV1 (% pred) | 86 | 86 | 85 | 84 | |
| Bronchodilator reversibility (%) | 10 | 10 | 10 | 11 | |
| β2 agonist use (puffs/24 h) | 2.9 | 3.2 | 2.9 | 2.7 | |
| Mean (SD) BMD (g/cm2) | |||||
| Lumbar spine | 1.15 (0.16) | 1.15 (0.16) | 1.13 (0.16) | 1.19 (0.17) | |
| Hip | 0.98 (0.16) | 0.96 (0.15) | 0.97 (0.17) | 1.0 (0.15) | |
| Total body | 1.17 (0.1) | 1.17 (0.1) | 1.19 (0.1) | 1.19 (0.09) | |
| Vertebral deformity (%) | 8 | 7 | 7 | 9 | |
| Biochemical markers geometric mean (range): | |||||
| Osteocalcin (μg/l) | 2.6 (0.5–21.3) | 2.3 (0.5–21.3) | 2.8 (0.5–18.4) | 2.3 (0.5–12.5) | |
| Deoxypyridinoline (mol/mol creatinine) | 12.9 (3.3–78) | 12.5 (6.4–36) | 12.5 (3.3–40) | 12.8 (3.6–47) | |
| Pyridinoline crosslinks (μmol/mol creatinine) | 48.1 (12.6–144) | 48.0 (21–125) | 45.7 (15.6–111) | 46.0 (19–136) | |
BUD = budesonide; BDP = beclomethasone dipropionate; PEF = peak expiratory flow; FEV1 = forced expiratory flow in one second; BMD = bone mineral density.